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Abstract
Head and neck squamous cell carcinoma (HNSCC) is the sixth most frequent cancer world-
wide. The pregnane X receptor (PXR) is a nuclear receptor regulating several target genes
associated with cancer malignancy. We here demonstrated a significant effect of PXR on
HNSCC cell growth, as evidenced in PXR knock-down experiments. PXR transcriptional
activity is more importantly regulated by the presence of coactivators and corepressors than
by PXR protein expression. To date, there is scarce information on the regulation of PXR in
HNSCC and on its role in the pathogenesis of this disease. Coactivator and corepressor
expression was screened through qRT-PCR in 8 HNSCC cell lines and correlated to PXR
activity, determined by using a reporter gene assay. All cell lines considerably expressed all
the cofactors assessed. PXR activity negatively correlated with nuclear receptor corepres-
sor 2 (NCoR2) expression, indicating a major role of this corepressor in PXR modulation
and suggesting its potential as a surrogate for PXR activity in HNSCC. To test the associa-
tion of NCoR2 with the malignant phenotype, a subset of three cell lines was transfected
with an over-expression plasmid for this corepressor. Subsequently, cell growth and che-
moresistance assays were performed. To elucidate the mechanisms underlying NCoR2
effects on cell growth, caspase 3/7 activity and protein levels of cleaved caspase 3 and
PARP were evaluated. In HNO97 cells, NCoR2 over-expression decreased cell growth,
chemoresistance and increased cleaved caspase 3 levels, caspase activity and cleaved
PARP levels. On the contrary, in HNO124 and HNO210 cells, NCoR2 over-expression
increased cell growth, drug resistance and decreased cleaved caspase 3 levels, caspase
activity and cleaved PARP levels. In conclusion, we demonstrated a role of PXR and
NCoR2 in the modulation of cell growth in HNSCC. This may contribute to a better under-
standing of the highly variable HNSCC therapeutic response.
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1. Introduction
Head and neck squamous cell carcinoma (HNSCC) comprises malignancies of the oral cavity, lar-
ynx, pharynx, nasal cavity and paranasal sinuses, representing the sixth most frequent cancer
worldwide. HNSCC treatment consists of surgery, radiotherapy and chemotherapy. However, in
spite of the improvement in the therapeutic strategies during the last decades, overall survival after
5 years remains between 40 and 50%. Molecular heterogeneity of HNSCC has been suggested as a
reason underlying the variable response rate to the conventional therapeutic approaches [1].
The pregnane X receptor (PXR, NR1I2) is a nuclear receptor originally described as a master
modulator of drug metabolism and disposition [2]. Moreover, recent investigations pointed out
a role of PXR in cancer pathogenesis. For instance, Wang et al. described a PXR-driven increase
in cell proliferation and metastatic potential in colon cancer [3]. In line with these observations,
an induction of the anti-apoptotic genes bcl-2 and bcl-xL and a down-regulation of the pro-apo-
ptotic genes BAK1 and p53 by PXR were reported [4,5]. Similar anti-apoptotic and pro-prolifer-
ative functions of PXR have been reported in models of breast-, endometrial-, ovarian- and
prostate cancer [6]. On the contrary, an anti-proliferative and pro-apoptotic role of PXR was
described in cervical cancer [7]. Although the expression of PXR in HNSCC is well-known [8],
the impact of PXR on the malignant phenotype in HNSCC has not been investigated yet.
Mechanistically, PXR regulates the transcription of target genes through binding as a heterodi-
mer with the retinoid X receptor alpha (RXRα) to response elements within the gene promoter
[2]. Previously, we have characterized PXR expression levels and PXR intrinsic activity in a set of
8 HNSCC cell lines. Our data demonstrated no correlation between PXR protein expression and
transcriptional activity, clearly indicating the presence of additional factors modulating PXR func-
tion [8]. Nuclear receptor cofactors are proteins physically interacting with nuclear receptors, thus
affecting their functionality and biological effects. They can be divided into coactivators and core-
pressors with a higher expression of coactivators or corepressors resulting in an increased or
reduced transcriptional activity of the associated receptor, respectively [9, 10]. PXR coactivators
include the steroid receptor coactivators (SRCs) 1, 2 and 3, the peroxisome proliferator-activated
receptor-gamma coactivator 1-alpha (PGC1α) and the p300 protein [11–13]. On the other side,
PXR corepressors include the nuclear receptor corepressor 1 (NCoR1), the nuclear receptor core-
pressor 2 (NCoR2, also known as silencing mediator of retinoid and thyroid hormone receptor,
SMRT) and the small heterodimer partner (SHP/NR0B2) [2, 10]. As previously described for
PXR, a role of several cofactors in cancer pathogenesis has been already reported. For instance,
higher SRC1, SRC2 or SRC3 expression was associated with a worse prognosis in breast cancer,
prostate cancer or triple negative breast cancer patients, respectively [14–16]. In a similar way,
corepressors can also influence cancer prognosis. For example, NCoR2 was described as a marker
of earlier recurrence and poor outcome in breast carcinoma patients [17, 18]. To date, there is no
information concerning PXR cofactor expression, their regulatory role on PXR transcriptional
activity or their relevance for the malignant phenotype in HNSCC.
The aim of this work was to evaluate the effect of PXR and its regulatory cofactors on the
cell growth, chemoresistance and apoptosis in HNSCC cell lines. A better understanding of
the relevance of PXR and its regulation may help to identify potential prognostic markers bet-
ter reflecting the molecular heterogeneity of HNSCC.
2. Materials and methods
2.1. Materials
Cisplatin, staurosporine and fetal bovine serum were from Sigma-Aldrich (Taufkirchen, Ger-
many). Crystal violet, paclitaxel and 5-fluorouracil (5-FU) were from Applichem (Darmstadt,
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Germany). Primary antibodies used were: cleaved caspase 3 (Asp175, #9661, 1:1000) and
cleaved poly ADP-ribose polymerase (PARP, Asp214, #9546, 1:2000) from Cell Signaling (Lei-
den, Netherlands); β-actin (AC-15, 1:10000) from Sigma-Aldrich (Taufkirchen, Germany);
NCoR2 (ab24551, 1:1000) from Abcam (Cambridge, UK); GAPDH (G-9, 1:1000); Histone H1
(AE-4, 1:1000) and PXR (G-11, 1:100) from Santa Cruz Biotechnology (Heidelberg, Germany).
Cleaved PARP, β-actin, GAPDH, Histone H1 and PXR antibodies were mouse monoclonal
antibodies. Cleaved caspase 3 and NCoR2 were rabbit polyclonal antibodies. All antibodies
were raised against the corresponding human antigens.
2.2. Cell lines
HNSCC cell lines (HNO97, HNO124, HNO150, HNO206, HNO210, HNO388, HNO413 and
HNO432) used in the current work were established from intraoperatively obtained samples,
characterized and cultured as already described (Table 1) [8, 19]. Cells were grown in polysty-
rene flasks and plates in Dulbecco’s modified Eagle’s medium supplemented with fetal bovine
serum (10% v/v), penicillin (100 U/mL) and streptomycin (0.1 mg/mL). All cell lines were neg-
atively tested for infection withMycoplasma using the PCRMycoplasma Test Kit (Applichem,
Darmstadt, Germany) following the manufacturer’s instructions.
2.3. PXR knock-down
To elucidate whether PXRmodulates cell growth in HNSCC, PXR expression was silenced in a
set of three cell lines basally displaying high PXR activity (HNO97, HNO124 and HNO210
cells). Cells were transfected with 4 μg of the pLKO.1-PXR shRNA vector (Sigma-Aldrich, Tauf-
kirchen, Germany) encoding a short hairpin RNA (shRNA) targeting human PXR (PXR- cells).
Control cells were transfected with the pLKO.1-scrambled vector encoding a non-silencing
shRNA (PXR+ cells) (Sigma-Aldrich, Taufkirchen, Germany). Transfections were performed by
electroporation using the V-kit from Lonza (Basel, Switzerland) as previously described [8]. The
efficacy of PXR knock-down was quantitatively verified at 72 h post-transfection through
qRT-PCR (see section 2.4). PXR silencing was further verified at the protein level through west-
ern blot as previously described [8]. For cell growth evaluation, transfected cells were seeded in
96-well plates, incubated for 72 h and subjected to crystal violet staining as described in 2.5.
2.4. mRNA expression analysis
The expression of PXR, its heterodimerization partner RXRα, the coactivators SRC1, SRC2,
SRC3, p300 and PGC1α as well as the corepressors NCoR1, NCoR2 and SHP was quantified at
Table 1. HNSCC cell lines used in the current study.
Cell line Localization PXR intrinsic activity (arbitrary units)
HNO97 Oral cavity 35.9 ± 6.8
HNO124 Oral cavity 8.6 ± 0.7
HNO150 Larynx 2.6 ± 0.5
HNO206 Oropharynx 0.8 ± 0.4
HNO210 Larynx 16.7 ± 4.0
HNO388 Nasal cavity 2.8 ± 0.3
HNO413 Oropharynx 2.2 ± 0.5
HNO432 Hypopharynx 1.1 ± 0.2
Displayed is the localization of each HNSCC cell line used in the current study as well as the PXR intrinsic activity [8,
19].
https://doi.org/10.1371/journal.pone.0193242.t001
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the mRNA level through qRT-PCR with calibrator-normalized relative quantification with
efficiency correction using a LightCycler1 480 device (Roche Applied Science, Mannheim,
Germany). For this purpose, total RNA was isolated using the GenElute Mammalian Total
RNAMiniprep Kit (Sigma-Aldrich, Taufkirchen, Germany) and reverse transcribed using the
RevertAid HMinus First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham,
USA). qPCR reactions were performed using the ABsolute qPCR SYBR Green mix (Thermo
Fisher Scientific, Waltham, USA). Specificity of the amplification was verified by conducting a
melting curve with continuous fluorescence measurement. The most suitable housekeeping
gene was selected among a panel consisting of 7 genes [60S acidic ribosomal protein P0
(HUPO), β2-microglobuline (B2MG), beta-glucuronidase (BGU), glucose-6-phosphate dehydro-
genase (G6PDH), hypoxanthine-guanine phosphoribosyltransferase (HPRT), RNA polymerase II
(RPII) and ribosomal protein L13 (RPL13)], using the geNorm software (Version 3.4, Center
for Medical Genetics, Ghent, Belgium) [20]. RPII showed the highest stability in the different
cell lines and thus was selected as a reference gene for the following expression studies. Primer
sequences and thermal profiles are provided as supplementary material (S1 Table).
2.5. Cell growth
Cell growth was evaluated by using the crystal violet method as previously described [21].
Briefly, HNO97, HNO124 and HNO210 cells were transfected or transfected and treated,
according to each particular experiment. After the corresponding incubation time, cells were
stained with a crystal violet solution for 15 min at room temperature. Subsequently, cells were
rinsed, crystal violet was solubilized in methanol and absorbance was measured at 555 nm.
2.6 Correlation between coactivator- and corepressor expression and PXR
activity
PXR activity was quantified using a reporter system consisting of the plasmids
pGL4.21-PXRRE and pGL4.74. pGL4.21-PXRRE codifies firefly luciferase under the control of
two PXR response elements. The size and position of the inserts was corroborated by agarose
gel electrophoresis and plasmid sequentiation [8]. pGL4.74 (Promega, Mannheim, Germany)
codifies Renilla luciferase under the control of a constitutive promoter and was used for nor-
malization purposes. PXR activity resulted from the ratio between firefly luciferase and Renilla
luciferase signals, measured using the Dual-Glo1 luciferase assay system (Promega, Mann-
heim, Germany). Correlation between PXR activity and coactivator- and corepressor expres-
sion was analyzed using GraphPad Prism 7.02 (GraphPad Software, San Diego, USA). Normal
distribution of data was evaluated using the Kolmogorov-Smirnov test. Since datasets were not
normally distributed, the correlation between expression and activity values was assessed
using the non-parametric Spearman’s method.
2.7. NCoR2 over-expression and effect on PXR activity
PXR regulation by NCoR2 was further confirmed in a gain-of-function model. For this pur-
pose, NCoR2 was over-expressed in HNO97, HNO124 and HNO210 cells, which originally
display low basal NCoR2 expression and high PXR activity (Table 1) [8]. Cells were transfected
with 1 μg of the pCMV6-NCoR2 plasmid (Clone RC212113, Origene, Rockville, USA) encod-
ing the transcript variant 1 of the corepressor, previously described as the main NCoR2 iso-
form interacting with PXR [22]. Control cells were transfected with 1 μg of the empty pCMV6
vector (Clone PS100001, Origene, Rockville, USA). All transfections were performed as
described [8]. NCoR2 over-expression was verified at the mRNA level at 12 h post-transfection
as described in 2.4. NCoR2 expression at the protein level was evaluated through western blot
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as described previously [8, 21]. NCoR2 effect on PXR activity was assessed by cotransfection of
the pCMV6-NCoR2 plasmid together with the PXR reporter system described in 2.6.
2.8. Effect of NCoR2 on cell growth and chemoresistance
The effect of NCoR2 on cell growth was evaluated by using the crystal violet method as previ-
ously described (see section 2.5). Briefly, HNO97, HNO124 and HNO210 cells were trans-
fected with pCMV6-NCoR2 or with the pCMV6 empty plasmid as described in 2.7. Following,
cells were seeded in 96-well plates and incubated for 72 h. Then, cells were stained and crystal
violet absorbance was measured at 555 nm. To evaluate whether NCoR2 over-expression mod-
ulates resistance to chemotherapeutic agents usually administered in HNSCC treatment, trans-
fected cells were seeded in 96-well plates (10000 cells/well for HNO97 and HNO124 cells and
5000 cells/well for HNO210 cells), incubated for 24 h and exposed to different concentrations
of 5-FU (0.5–25000 μM), cisplatin (0.01–200 μM) or paclitaxel (0.01–500 nM) for 48 h. Then,
crystal violet absorbance was measured. Cell viability was plotted against the decimal loga-
rithm of drug concentration and fitted to a sigmoidal curve using Graph Pad Prism 7.02
(GraphPad Software, San Diego, USA). Resistance to the different chemotherapeutic agents
was expressed in terms of the concentration leading to 50% of cell death (IC50).
2.9. Effect of NCoR2 on apoptosis
To evaluate whether apoptosis could be a mechanism underlying the NCoR2 effects on cell
growth, caspase 3- and 7- activities were quantified using the Caspase-Glo1 3/7 Assay (Pro-
mega, Mannheim, Germany) following manufacturer’s instructions. Briefly, cells were trans-
fected with NCoR2 over-expression- or the corresponding empty vector as described in 2.7,
seeded in 96-well plates (12500 cells/well) and cultured for 24 h. Then, cells were incubated for
30 min with a luminogenic caspase 3/7 substrate. Subsequently, luminescence was measured
using a GloMax luminometer (Promega, Mannheim, Germany). Caspase associated lumines-
cence was normalized to the total number of cells, assessed using the CytoTox-GloTM assay
(Promega, Mannheim, Germany) following manufacturer’s instructions. Staurosporine (1 μM,
24 h) was used as a positive control of apoptosis induction [23]. Furthermore, the protein levels
of cleaved PARP (Asp214), which results from caspase 3-catalyzed proteolysis of PARP [24] as
well as the protein levels of cleaved (active) caspase 3 (Asp175) were evaluated in
pCMV6-NCoR2- and empty vector-transfected cells. For this purpose, total lysates were pre-
pared with RIPA buffer 24 h post-transfection and subjected to SDS-PAGE and western blot
as previously described [8, 21].
2.10. Statistical analysis
Statistical analysis was performed using GraphPad Prism 7.02 software (GraphPad Software,
San Diego, USA). All experiments were repeated at least three times. Statistical differences
between groups were evaluated using the Student’s t-test and significance was set at p<0.05.
Data are presented as mean ± S.D.
3. Results
3.1. Effect of PXR on HNSCC cell growth
To evaluate the modulation of cell growth by PXR, the expression of the nuclear receptor was
silenced in HNO97, HNO124 and HNO210 cells using a specific shRNA. PXR expression at
the mRNA level was down-regulated by 79%, 64% and 54% in HNO97 (Fig 1A), HNO124 (Fig
1B) and HNO210 PXR- cells (Fig 1C), respectively. Silencing was further confirmed at the
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protein level (Fig 1D). Under these conditions, HNO97 PXR- cells exhibited a decreased cell
growth (-52%) compared to scrambled shRNA-transfected PXR+ cells (Fig 1E). On the con-
trary, HNO124 and HNO210 PXR- cells exhibited an increase in the cell growth (+36% and
+111%, respectively) (Fig 1F and 1G). These results confirm a modulation of cell growth by
PXR in HNSCC, as previously described for other tumor types.
Fig 1. PXR knock-down and effect on cell growth in HNSCC cell lines. Cells were transfected with pLKO.1-PXR shRNA plasmid encoding a shRNA directed
against human PXR (PXR- cells) or the pLKO.1-scr vector encoding a scrambled, non-silencing shRNA (PXR+ cells). PXRmRNA expression was quantified
through qRT-PCR in HNO97 (a), HNO124 (b) and HNO210 (c) cells. RPII was used as a housekeeping gene. mRNA data were normalized to PXR expression in
PXR+ cells, set to 1. Data are expressed as mean ± S.D. ⇤significantly different from PXR+ cells, p<0.05, n = 3. PXR knock-down was also verified at the protein
level through western blot analysis using GAPDH as a loading control. Representative images and histograms are shown for each cell line (d). The effect of PXR
knock-down on cell growth was assessed at 72 h post-transfection in HNO97 (e), HNO124 (f) and HNO210 (g) cells using the crystal violet method. Results
were normalized to cell growth in cells transfected with a non-silencing shRNA (PXR+ cells), set to 1. Data are expressed as mean ± S.D. ⇤significantly different
from PXR+ cells, p<0.05, n = 3.
https://doi.org/10.1371/journal.pone.0193242.g001
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3.2. Expression of coactivators and corepressors in HNSCC cell lines
Considering the potential importance of PXR for HNSCC malignant phenotype and the well-
known dissociation between PXR expression and PXR transcriptional activity in HNSCC [8],
the expression pattern of PXR cofactors was assessed as a possible mechanism contributing to
this observation. All the HNSCC cell lines evaluated showed a considerable mRNA expression
of the coactivators p300, SRC1, SRC2, SRC3 (Fig 2A, 2C–2E), as well as of the corepressors
NCoR1, NCoR2 and SHP (Fig 2G–2I). In addition, the PXR partner RXRα also exhibited a
detectable signal in all the cell lines (Fig 2F). PGC1α expression was detected in all cell lines,
whereas HNO206, HNO210 and HNO388 cells exhibited notably higher expression levels
than the other cell lines evaluated (Fig 2B). These data confirm the presence of the above-men-
tioned cofactors in HNSCC, as demonstrated for other tumor diseases, and suggest a potential
role in the modulation of PXR in this tumor disease.
3.3. Correlation between coactivator- and corepressor expression and PXR
activity
The association between the expression of each coactivator and corepressor (Fig 2) and PXR
activity data previously obtained by our group (Table 1) [8] was assessed in the panel of 8
HNSCC cell lines through the Spearman’s correlation method. Results for all cofactors are pre-
sented in Table 2. A significant negative correlation was observed between NCoR2 expression
and PXR activity, indicating indeed a major role of this corepressor in the modulation of PXR
activity in HNSCC (Table 2). In contrast, expression of p300, PGC1α, SRC1, SRC2, SRC3,
NCoR1, SHP and RXRα exhibited no significant correlation with PXR activity (Table 2).
3.4. Effect of NCoR2 over-expression on PXR activity
To confirm NCoR2 role as a negative modulator of PXR activity, the nuclear receptor was
over-expressed in three selected cell lines. Transfection of HNO97, HNO124 and HNO210
cells with the pCMV6-NCoR2 plasmid resulted in a significant increase in NCoR2 mRNA
expression at 12 h post-transfection (+2136%, +2592% and +11408% in HNO97, HNO124
and HNO210 cells, respectively) compared to empty vector transfected cells (Fig 3A–3C).
Over-expression was also verified at the protein level (Fig 3D). As expected, NCoR2 over-
expression resulted in a significant decrease in PXR activity (-35%, -50% and -56% in HNO97,
HNO124 and HNO210 cells, respectively) (Fig 3E–3G), further confirming a major role of
NCoR2 in the regulation of this nuclear receptor in HNSCC.
3.5. Effect of NCoR2 over-expression on cell growth and chemoresistance
PXR and NCoR2 have been reported to modulate malignancy of cancer types other than
HNSCC. We here observed a cell line-specific effect of NCoR2 over-expression with a decrease
in HNO97 cell growth (-22%) (Fig 3H) and, on the contrary, an increase in HNO124 and
HNO210 cell growth (+143 and +25%, respectively) compared to empty vector transfected
cells (Fig 3I and 3J).
In addition, NCoR2 over-expression modified the resistance to chemotherapeutic agents
usually administered in HNSCC treatment. In particular, NCoR2 over-expressing HNO97
cells exhibited a diminished resistance to cisplatin and paclitaxel, whereas NCoR2 over-expres-
sion resulted in an enhanced resistance to 5-FU, cisplatin and paclitaxel in HNO124 and
HNO210 cells (Table 3).
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3.6. Effect of NCoR2 over-expression on apoptosis
To evaluate whether changes in the apoptosis rate underlie the effect of NCoR2 over-expres-
sion on cell growth, we evaluated caspase 3/7 activities. HNO97 cells showed an increase in
Fig 2. Cofactor expression in HNSCC cell lines. The expression of p300 (a), PGC1α (b), SRC1 (c), SRC2 (d) and SRC3 (e) as nuclear receptor
coactivators, RXRα (f) as PXR heterodimerization partner and NCoR1 (g), NCoR2 (h) and SHP (i) as nuclear receptor corepressors was assessed at
mRNA level in a set of 8 HNSCC cell lines through qRT-PCR. The expression of the different target genes was normalized to RNA Polymerase II (RPII)
expression, used as housekeeping gene. Data are expressed as mean ± S.D. (n = 3). To allow for comparisons between cell lines, results were normalized to
the expression in HNO97 cells, set to 1.
https://doi.org/10.1371/journal.pone.0193242.g002
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caspase 3/7 (+86%) activity by NCoR2 over-expression cells compared to empty vector trans-
fected cells (Fig 4A), agreeing well with the reduced cell growth. On the contrary, NCoR2
over-expressing HNO124 and HNO210 cells exhibited a decrease in caspase 3/7 activity (-14%
and -13%, respectively) (Fig 4B and 4C), indicating a reduction of the cell population undergo-
ing apoptosis and probably explaining the increase in the cell growth previously observed (Fig
3). Treatment with staurosporine (1 μM, positive control for apoptosis) for 24 h resulted in a
significant increase in caspase 3/7 activity in all the cell lines used (Fig 4D–4F). In addition,
NCoR2 over-expression resulted in a significant increase in the expression of cleaved caspase 3
and cleaved-PARP in HNO97 cells (Fig 5A). On the contrary, HNO124 and HNO210 cells
exhibited a significant decrease in cleaved caspase 3 and cleaved PARP (Fig 5B and 5C) agree-
ing well with the reduced caspase 3/7 activity and supporting an inhibitory effect of NCoR2 on
the apoptosis in these cell lines.
4. Discussion
Molecular heterogeneity is likely to be one of the reasons underlying the variable response to
different therapeutic strategies and the poor overall survival in HNSCC [1]. Nuclear receptors
and their cofactors modulate several signal pathways related to cancer malignancy. In the pres-
ent work, we described opposite effects of PXR on cell growth in HNSCC according to the par-
ticular cell line (Fig 1). Differential effects of PXR on cell growth, even within the same cancer
type, have been described for instance in colon cancer. Here, an inhibition of p53 transcrip-
tional activity and a promotion of the malignant phenotype have been described [25]. Simi-
larly, stimulation of tumor malignancy by PXR via the activation of the fibroblast growth
factor 19 (FGF19) was reported [3]. Conversely, p21 up-regulation and inhibition of prolifera-
tion by PXR have been also described in another model of the same disease [26]. Our results
here, demonstrating a significant role of PXR in HNSCC pathogenesis, highlight the impor-
tance of further studying this nuclear receptor as a factor contributing to HNSCC molecular
heterogeneity and variable therapeutic response.
Previously, we have described the dissociation between PXR expression and transcriptional
activity in HNSCC. Indeed, the differential activation of a reporter gene under the control of a
PXR responsive promoter could not be explained in terms of PXR protein levels [8]. Coactiva-
tors and corepressors are key determinants of PXR activity, especially in the absence of an
external ligand [2, 10, 13]. We here characterized the expression pattern of the most important
Table 2. Correlation between coactivator- and corepressor expression and PXR transcriptional activity.
Coactivator or corepressor r p-value
p300 -0.571 0.15
PGC1α -0.381 0.36
SRC1 -0.690 0.07
SRC2 0.167 0.70
SRC3 -0.333 0.43
RXRα -0.048 0.94
NCoR1 -0.310 0.46
NCoR2 -0.810 0.02
SHP -0.143 0.75
Expression of coactivators and corepressors as well as of the PXR partner RXRα was correlated to the PXR activity in
the set of 8 HNSCC cell lines used in the present study. Displayed are the Spearman’s correlation coefficients (r) and
the p-value, n = 3. Statistical significance was set at p<0.05.
https://doi.org/10.1371/journal.pone.0193242.t002
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PXR coactivators and corepressors in a set of HNSCC cell lines. All coactivators and corepres-
sors investigated were expressed in all the HNSCC cell lines used (Fig 2). So far, clinical evi-
dence suggests a crucial role of these accessory proteins in cancer prognosis. For instance,
several clinical studies associated p300 expression with melanoma, colorectal or lung cancer
prognosis [27–29]. For SRC1, -2 and -3 a similar role was suggested in diverse malignancies
[14–16]. Likewise, corepressors have also been associated with response to treatment and prog-
nosis in lung, liver and breast cancer [17, 18]. In general, cancer initiation, promotion, pro-
gression, metastases formation as well as response to treatment are the result of the interplay
of a large number of genes [30]. Among them, cyclooxygenase 2 (COX2), the chemokine
receptor CXCR4 and the matrix metalloproteinase 9 (MMP9) as well as apoptosis related
genes are associated with the malignant phenotype of HNSCC and have been shown to be reg-
ulated by variable levels of nuclear receptor cofactors, albeit in other models [31–33]. Notewor-
thy, a modulation of COX2 and CXCR4 levels by NCoR2 was observed [34]. Our results
demonstrating a significant expression of p300, SRC1, NCoR1 and NCoR2, among other
cofactors, suggest a possible regulation of the above-mentioned malignancy associated genes
also in HNSCC.
In the present work, we demonstrated a negative correlation (r = -0.810; p = 0.02) between
NCoR2 expression and PXR activity (Table 2). Furthermore, this regulation was confirmed
using a gain-of-function model in a subset of 3 cell lines exhibiting lower basal NCoR2 expres-
sion and higher PXR activity. These observations clearly suggest NCoR2 expression as a surro-
gate for PXR activity in HNSCC. Taking into consideration the association between NCoR2,
PXR and cancer malignancy, we evaluated whether NCoR2 can indeed alter cell growth in
HNSCC. Interestingly, our results demonstrated a cell line-specific effect displaying the same
pattern exhibited in PXR knock-down experiments. NCoR2 over-expression (i.e. lower PXR
activity) inhibited cell growth in the HNO97 cell line, agreeing well with the inhibition in cell
growth observed under PXR silencing (Fig 1). Conversely, NCoR2 over-expression stimulated
growth in HNO124 and HNO210 cells (Fig 3), also agreeing with the increased cell growth in
Fig 3. Effect of NCoR2 over-expression on PXR activity and cell growth in HNO97, HNO124 and HNO210 cells. Cells were transfected
with the pCMV6-NCoR2 plasmid (or the empty vector pCMV6). NCoR2 over-expression was quantified at the mRNA level through
qRT-PCR at 12 h post-transfection in HNO97 (a), HNO124 (b) and HNO210 (c) cells. RPII was used as housekeeping gene. mRNA data
were normalized to NCoR2 expression in cells transfected with the pCMV6 empty vector, set to 1. NCoR2 over-expression was verified at
the protein level at the same time point through western blot analysis using histone H1 as a loading control. Representative images are
shown for each cell line (d). PXR activity was measured at 48 h post-transfection in HNO97 (e), HNO124 (f) and HNO210 (g) cells. Cell
growth was measured at 72 h post-transfection in HNO97 (h), HNO124 (i) and HNO210 (j) cells using the crystal violet method. Results
were normalized to PXR activity or cell growth in cells transfected with the pCMV6 empty vector, set to 1. All data are expressed as
mean ± S.D. ⇤significantly different from pCMV6-transfected cells, p<0.05, n = 3–4.
https://doi.org/10.1371/journal.pone.0193242.g003
Table 3. Drug resistance assays.
Cell line 5-FU (μM) Cisplatin (μM) Paclitaxel (nM)
HNO97 pCMV6 6.7 ± 2.1 6.6 ± 0.2 7.7 ± 0.6
pCMV6-NCoR2 7.3 ± 1.7 4.3 ± 0.5⇤ 5.4 ± 0.9⇤
HNO124 pCMV6 10.9 ± 0.7 10.2 ± 0.6 4.6 ± 0.1
pCMV6-NCoR2 14.2 ± 1.6⇤ 12.6 ± 0.9⇤ 6.0 ± 0.5⇤
HNO210 pCMV6 5.5 ± 0.5 1.6 ± 0.2 2.0 ± 0.6
pCMV6-NCoR2 8.0 ± 1.2⇤ 2.3 ± 0.1⇤ 3.3 ± 0.4⇤
Displayed are the IC50 of 5-FU, cisplatin and paclitaxel in pCMV6 and pCMV6-NCoR2 transfected HNO97, HNO124 and HNO210 cells.
⇤significantly different from the corresponding pCMV6-transfected cells, p<0.05, n = 3.
https://doi.org/10.1371/journal.pone.0193242.t003
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HNO124 and HNO210 PXR- cells (Fig 1). This similarity between PXR silencing and NCoR2
over-expression experiments further indicates a functional association between PXR and
NCoR2, as described in other models [2, 10]. In addition, NCoR2 over-expression led to an
increase in caspase 3/7 activity in HNO97 cells (Fig 4) and an increase in the protein levels of
cleaved caspase 3 and cleaved PARP (Fig 5), possibly accounting for the decrease in the cell
growth in this cell line. On the contrary, NCoR2 led to a decrease of caspase activation in
NCoR2 over-expressing HNO124 and HNO210 cells, as observed through activity measure-
ments (Fig 4) and western blot studies (Fig 5), in accordance with the effects on cell growth.
Noteworthy, our results agree with previous reports demonstrating a modulation of apoptosis
by this same corepressor. For example, Song et al. described an increase in apoptosis of non-
Hodgkin lymphoma cell lines by NCoR2 [35]. On the contrary, NCoR2 reduced apoptosis in
breast cancer cell lines [23]. Our data as well as previous studies, although remarking the
NCoR2 importance in cancer growth, evidence differential NCoR2 effects in different models.
Fig 4. Caspase activity in NCoR2 over-expressing HNO97, HNO124 and HNO210 cells. Cells were transfected with pCMV6-NCoR2 plasmid (or
the empty vector pCMV6). Caspase activity was assessed at 24 h post-transfection in HNO97 (a), HNO124 (b) and HNO210 (c) cells. Results were
normalized to the corresponding activity in cells transfected with the pCMV6 empty vector, set to 1. ⇤significantly different from pCMV6-transfected
cells, p<0.05, n = 3. As a positive control, cells were treated with staurosporine (1 μM, 24 h), a known inductor of apoptosis. Subsequently, caspase
activity was assessed in HNO97 (d), HNO124 (e) and HNO210 (f) cells. Results were normalized to the corresponding measurements in control cells
(vehicle treated), set to 1. Data are expressed as mean ± S.D. ⇤significantly different from control cells, p<0.05, n = 3.
https://doi.org/10.1371/journal.pone.0193242.g004
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Noteworthy, HNO97 cells were derived from a tumor with a higher grading than HNO124
and HNO210 cells [19]. If these observations translated to an in vivo situation, NCoR2 expres-
sion might have opposite prognostic implications according to the molecular milieu, tumor
grading and stage of the disease.
Chemotherapy represents one of the milestones of HNSCC treatment. In the present work,
we observed an increased HNO97 cell sensitivity to cisplatin and paclitaxel through NCoR2
over-expression (Table 3), probably associated with the reduced cell growth and increased
apoptosis exhibited. On the contrary, NCoR2 drove an increase in HNO124 and HNO210 cell
Fig 5. Cleaved caspase 3 and cleaved PARP expression in NCoR2 over-expressing HNO97, HNO124 and HNO210
cells. Cells were transfected with pCMV6-NCoR2 plasmid (or the empty vector pCMV6). Cleaved caspase 3 and
cleaved PARP protein levels were evaluated at 24 h post-transfection in HNO97 (a), HNO124 (b) and HNO210 (c)
cells through western blot. β-actin was used as a loading control. Representative western blot detections are shown for
each cell line. ⇤significantly different from pCMV6-transfected cells, p<0.05, n = 3.
https://doi.org/10.1371/journal.pone.0193242.g005
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resistance to 5-fluorouracil, cisplatin and paclitaxel, agreeing well with the enhanced cell
growth and reduced apoptosis observed. Response to chemotherapeutic agents is governed by
multiple factors. Among them, proteins like p53, COX2 and CXCR4 can also contribute to the
enhanced chemoresistance, as already demonstrated in clinical studies [33, 36–38]. Since p53,
COX2 and CXCR4 are well-known PXR and NCoR2 targets, they constitute potential media-
tors of NCoR2 effects on chemoresistance [34, 39]. If such association took place in vivo, the
analysis of NCoR2 expression levels may contribute to a better prediction of chemotherapy
response in HNSCC.
In conclusion, we have described a modulation of cell growth by PXR in HNSCC. Further-
more, we demonstrated the role of NCoR2 in the modulation of PXR activity in HNSCC, con-
stituting this corepressor as an indicator of PXR functionality in HNSCC. In line with these
findings, we demonstrated a major role of NCoR2 in the regulation of cell growth, chemoresis-
tance and apoptosis, probably as a consequence of its interaction with PXR. Although these
findings should be further validated in more complex experimental settings (e.g. animal mod-
els, clinical studies) and extrapolations from in vitro studies to an in vivo situation should
always be done cautiously, these results suggest a role of NCoR2 in the malignant phenotype of
HNSCC and point out a potential role of this protein as a biomarker.
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